Celladon, which is developing novel therapies for the treatment of heart disease, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol CLDN. J.P. Morgan and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
